EPHA2 and glioblastoma: Additional CAR target antigens in GBM include B7-H3 (86, 87), HER2 (88–90) and EphA2 (91), as demonstrated in preclinical studies, and in a phase I dose escalation clinical trial using a HER2-CAR (92).